SCHEMBL5440486

SCHEMBL5440486

O=[N+]([O-])c1ccc2nc(OCCN3CCOCC3)sc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.57
AHR P35869 1/20 0.57
LTA4H P09960 1/20 0.52
LMNA P02545 2/20 0.48
RAB9A P51151 3/20 0.48
APOBEC3G Q9HC16 2/20 0.48
NPC1 O15118 2/20 0.48
APOBEC3A P31941 1/20 0.48
MAPT P10636 4/20 0.48
SMN1; SMN2 Q16637 3/20 0.45
CYP3A4 P08684 1/20 0.45
TSHR P16473 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
HTT P42858 1/20 0.45
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
MAPK1 P28482 1/20 0.45
BLM P54132 1/20 0.45
PDK1 Q15118 1/20 0.44
KDM4E B2RXH2 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5437060 0.83 LTA4H (0.56) LTA4HRAB9ANPC1MAPTSMN1; SMN2
SCHEMBL15447882 0.81 LTA4H (0.56) ALDH1A1LTA4HRAB9ANPC1MAPT
SCHEMBL5212987 0.79 ALDH1A1 (0.68) ALDH1A1AHRLMNARAB9ANPC1
SCHEMBL3754832 0.77 ALDH1A1 (0.56) ALDH1A1AHRLMNARAB9AAPOBEC3G
SCHEMBL21682160 0.77 ALDH1A1 (0.61) ALDH1A1AHRLMNARAB9ANPC1
SCHEMBL14824501 0.75 RAB9A (0.79) ALDH1A1AHRRAB9AAPOBEC3GNPC1
SCHEMBL5436916 0.74 LTA4H (0.56) ALDH1A1LTA4HRAB9ANPC1KDM4E
SCHEMBL519451 0.74 LTA4H (0.71) ALDH1A1LTA4HLMNARAB9ANPC1
SCHEMBL3944864 0.73 CTSB (0.60) ALDH1A1LMNARAB9ANPC1MAPT
SCHEMBL2717838 0.73 CYP1A2 (0.52) ALDH1A1LMNARAB9ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249639-A1 Use of 9H-Purine-2,6-Diamine Derivatives in the Treatment of Proliferative Diseases and Novel 9H-Purine-2,6-Diamine Derivatives BAENTELI ROLF 2007-10-25 US claimed
EP-1734968-A2 USE OF 9H-PURINE-2,6-DIAMINE DERIVATIVES IN THE TREATMENT OF PROLIFERATIVE DISEASES AND NOVEL 9H-PURINE-2,6-DIAMINE DERIVATIVES Novartis AG (CH) 2006-12-27 EP claimed
WO-2005097135-A2 USE OF 9H-PURINE-2,6-DIAMINE DERIVATIVES IN THE TREATMENT OF PROLIFERATIVE DISEASES AND NOVEL 9H-PURINE-2,6-DIAMINE DERIVATIVES NOVARTIS AG (CH) 2005-10-20 WO claimed
US-20070249639-A1 Use of 9H-Purine-2,6-Diamine Derivatives in the Treatment of Proliferative Diseases and Novel 9H-Purine-2,6-Diamine Derivatives BAENTELI ROLF 2007-10-25 US disclosed
EP-1734968-A2 USE OF 9H-PURINE-2,6-DIAMINE DERIVATIVES IN THE TREATMENT OF PROLIFERATIVE DISEASES AND NOVEL 9H-PURINE-2,6-DIAMINE DERIVATIVES Novartis AG (CH) 2006-12-27 EP disclosed
WO-2005097135-A2 USE OF 9H-PURINE-2,6-DIAMINE DERIVATIVES IN THE TREATMENT OF PROLIFERATIVE DISEASES AND NOVEL 9H-PURINE-2,6-DIAMINE DERIVATIVES NOVARTIS AG (CH) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249639-A1 Use of 9H-Purine-2,6-Diamine Derivatives in the Treatment of Proliferative Diseases and Novel 9H-Purine-2,6-Diamine Derivatives HPRT1, NUDT1, DPYD ALDH1A1 1136/4885AHR 1021/4885LTA4H 3544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.